This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2011 Dec 20;9(2):67-8.

doi: 10.1038/nrgastro.2011.249.

Hepatitis C in 2011: A new standard of care and the race towards IFN-free therapy

Wolf Peter Hofmann¹, Stefan Zeuzem

Affiliations

PMID: 22183183
DOI: 10.1038/nrgastro.2011.249

Review

Hepatitis C in 2011: A new standard of care and the race towards IFN-free therapy

Wolf Peter Hofmann et al. Nat Rev Gastroenterol Hepatol. 2011.

. 2011 Dec 20;9(2):67-8.

doi: 10.1038/nrgastro.2011.249.

Authors

Wolf Peter Hofmann¹, Stefan Zeuzem

Affiliation

¹ POLIKUM Friedenau Berlin, POLIKUM MVZ GmbH, Rubensstraβe 119, 12157 Berlin, Germany.

PMID: 22183183
DOI: 10.1038/nrgastro.2011.249

No abstract available

PubMed Disclaimer

Similar articles

Decade in review-HCV: hepatitis C therapy-a fast and competitive race.
Zeuzem S. Zeuzem S. Nat Rev Gastroenterol Hepatol. 2014 Nov;11(11):644-5. doi: 10.1038/nrgastro.2014.164. Epub 2014 Sep 16. Nat Rev Gastroenterol Hepatol. 2014. PMID: 25223875 Review. No abstract available.
The results of Phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending.
Pawlotsky JM. Pawlotsky JM. Gastroenterology. 2011 Mar;140(3):746-54. doi: 10.1053/j.gastro.2011.01.028. Epub 2011 Jan 18. Gastroenterology. 2011. PMID: 21255572 No abstract available.
The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naïve patients.
Nelson DR. Nelson DR. Liver Int. 2011 Jan;31 Suppl 1:53-7. doi: 10.1111/j.1478-3231.2010.02391.x. Liver Int. 2011. PMID: 21205138 Review.
The role of triple therapy in HCV genotype 1-experienced patients.
Fried MW. Fried MW. Liver Int. 2011 Jan;31 Suppl 1:58-61. doi: 10.1111/j.1478-3231.2010.02410.x. Liver Int. 2011. PMID: 21205139
Hepatitis C drug development at a crossroads.
Nelson DR. Nelson DR. Hepatology. 2009 Oct;50(4):997-9. doi: 10.1002/hep.23208. Hepatology. 2009. PMID: 19787813 No abstract available.

See all similar articles

Cited by

Innate immune cell networking in hepatitis C virus infection.
Saha B, Szabo G. Saha B, et al. J Leukoc Biol. 2014 Nov;96(5):757-66. doi: 10.1189/jlb.4MR0314-141R. Epub 2014 Jul 7. J Leukoc Biol. 2014. PMID: 25001860 Free PMC article. Review.
Baseline MELD score predicts hepatic decompensation during antiviral therapy in patients with chronic hepatitis C and advanced cirrhosis.
Dultz G, Seelhof M, Herrmann E, Welker MW, Friedrich-Rust M, Teuber G, Kronenberger B, von Wagner M, Vermehren J, Sarrazin C, Zeuzem S, Hofmann WP. Dultz G, et al. PLoS One. 2013 Aug 1;8(8):e71262. doi: 10.1371/journal.pone.0071262. Print 2013. PLoS One. 2013. PMID: 23936497 Free PMC article.
Impact of host and virus genome variability on HCV replication and response to interferon.
Schweitzer CJ, Liang TJ. Schweitzer CJ, et al. Curr Opin Virol. 2013 Oct;3(5):501-7. doi: 10.1016/j.coviro.2013.06.005. Epub 2013 Jul 6. Curr Opin Virol. 2013. PMID: 23835049 Free PMC article. Review.

References

1. N Engl J Med. 2011 Jun 23;364(25):2405-16 - PubMed
1. Gastroenterology. 2011 Dec;141(6):2047-55; quiz e14 - PubMed
1. Hepatology. 2012 Mar;55(3):749-58 - PubMed
1. N Engl J Med. 2011 Jun 23;364(25):2417-28 - PubMed
1. N Engl J Med. 2011 Mar 31;364(13):1195-206 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information